Summary of Key Points from the Conference Call on the Medical Device Industry Industry Overview - The Chinese medical device industry has significant potential for domestic substitution, with certain segments still having room for improvement in localization rates [1][3][10] - Chinese companies are positioned to become global leaders in the context of globalization, leveraging strong innovation capabilities and manufacturing advantages [1][4][10] Core Insights and Arguments - The high-value consumables sector is expected to see a notable recovery by 2025, with investment opportunities in orthopedics, neurointervention, ophthalmology, and electrophysiology [1][5] - Companies such as Huatai Medical, MicroPort, Lepu Medical, Mindray, and United Imaging are highlighted for their growth potential [1][5] - The upstream medical device sector is experiencing a turning point, with companies like Meihua Medical and Yirui Technology poised for significant revenue growth due to innovative products [1][6] - The in vitro diagnostics (IVD) sector has faced challenges due to policy impacts, but a recovery is anticipated next year, with New Industry expected to see positive revenue growth in Q4 [1][7] - Strategic adjustments by Chinese medical device companies include cost reduction, technological innovation, transformation to consumer-oriented businesses, and overseas market expansion [1][9] Additional Important Insights - The global medical device market is approximately 4 to 5 times larger than China's market, which is projected to grow significantly [2][12] - Chinese companies are diversifying their overseas expansion strategies, which include R&D innovation, clinical registration, and patent layout to mitigate geopolitical risks [2][11][14] - The importance of innovation is emphasized as a key driver for growth, with a focus on new product development and emerging technologies such as AI and brain-computer interfaces [26][31] - The medical device industry is witnessing a trend towards mergers and acquisitions as a means for companies to enhance their product lines and market positions [33][36] Notable Companies and Their Strategies - Mindray Medical is leading in internationalization, with overseas revenue expected to reach 45% in 2024 [19] - United Imaging and BGI are also making significant strides in their respective markets, with notable growth in overseas business [19][24] - High-value consumables companies like Nanwei Medical and MicroPort are employing various strategies, including direct sales and ODM, to expand their international presence [21][22] Future Outlook - The medical device industry is expected to continue evolving, with significant opportunities in areas such as AI healthcare applications, home respiratory devices, and surgical robots [28][30] - The brain-computer interface technology is emerging as a key investment area, with China positioned as a global leader [31] - The overall sentiment is optimistic regarding the recovery and growth potential of the Chinese medical device market, particularly as companies adapt to changing market conditions and consumer demands [36]

Core Viewpoint - The stock price of United Imaging Healthcare has experienced fluctuations, with a recent decline of 2.00% on September 26, 2023, while the company has shown a year-to-date increase of 15.40% [1][2]. Financial Performance - For the first half of 2025, United Imaging Healthcare reported a revenue of 6.016 billion yuan, representing a year-on-year growth of 12.79%, and a net profit attributable to shareholders of 998 million yuan, which is a 5.03% increase compared to the previous year [2]. - The company has distributed a total of 534 million yuan in dividends since its A-share listing [3]. Stock Market Activity - As of September 26, 2023, the stock price was 145.77 yuan per share, with a total market capitalization of 120.138 billion yuan [1]. - The trading volume on that day was 405 million yuan, with a turnover rate of 0.33% [1]. - There was a net outflow of 26.2686 million yuan in principal funds, with large orders accounting for 24.25% of purchases and 27.33% of sales [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 23.01% to 16,500, while the average circulating shares per person increased by 29.89% to 35,953 shares [2]. - Major shareholders include the Huaxia SSE STAR 50 ETF, which increased its holdings by 3.2169 million shares, and the Hong Kong Central Clearing Limited, which raised its stake by 781.97 thousand shares [3].

Investment Rating - The investment rating for Shanghai United Imaging Healthcare Co is Equal-weight [10] Core Insights - The outlook for early 2026 in China indicates that the equipment upgrade programs initiated in 2025 are expected to support a sustainable industry recovery into the second half of 2025 and 2026, aided by larger funding and increased government support [1] - Management anticipates overseas growth in 2025 to reach the high end of the guided range of 35-50% year-over-year, with Europe expected to lead this growth at over 100% [2] - The company has achieved significant supply chain self-sufficiency, producing most of its <5MW CT tubes domestically while sourcing larger tubes from US and EU suppliers, aiming for increased internal production in the near future [3] Summary by Sections Financial Metrics - The current price target for Shanghai United Imaging Healthcare Co is Rmb158.00, representing a 6% upside from the closing price of Rmb148.75 on September 25, 2025 [10] - Projected revenue growth is expected to rise from Rmb10,300 million in 2024 to Rmb17,940.5 million by 2027 [10] - Earnings per share (EPS) are forecasted to increase from Rmb1.53 in 2024 to Rmb3.49 in 2027 [10] Market Position - The competitive landscape for high-end medical equipment in China shows a significant domestic market share, with imports declining in various segments [5][7] - The company is positioned to benefit from favorable regulatory developments and market share gains, alongside potential margin expansion through economies of scale [15]

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 上海联影医疗科技股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 投资者可于2025年9月26日（星期五）至10月10日(星期五)16:00前登录上证路演中心网站首页点击"提 问预征集"栏目或通过公司邮箱IR@united-imaging.com进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 上海联影医疗科技股份有限公司（以下简称"公司"）已于2025年8月30日发布公司2025年半年度报告。 为便于广大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于2025年10月13 日15:00-16:00举行2025年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2025年半年度经营成果、财务状况的具体情况与投 资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开 ...

9月25日，浩瀚深度收涨1.81%，收盘价为25.34元，发生1笔大宗交易，合计成交量20万股，成交金额 490万元。 第1笔成交价格为24.50元，成交20.00万股，成交金额490.00万元，溢价率为-3.31%，买方营业部为长江 证券股份有限公司北京百万庄大街证券营业部，卖方营业部为长江证券股份有限公司北京百万庄大街证 券营业部。 进一步统计，近3个月内该股累计发生3笔大宗交易，合计成交金额为1810万元。该股近5个交易日累计 上涨3.05%，主力资金合计净流出909.36万元。 责任编辑：小浪快报 ...

会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 证券代码： 688271 证券简称： 联影医疗 公告编号： 2025-039 上海联影医疗科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 13 日（星期一）15:00-16:00 投资者可于 2025 年 9 月 26 日（星期五）至 10 月 10 日(星期五)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@united-imaging.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 上海联影医疗科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日发布公司 2025 年半年度报告。为便于广大投资者更全面深入地了解公司 2025 年半年度经营 ...

Summary of Medical Device and Healthcare Services Industry Conference Call Industry Overview - The medical device sector is experiencing improved growth rates, with significant performance expected in Q3 and the second half of the year, suggesting a focus on companies with improving quarter-over-quarter and year-over-year results, as well as those poised for accelerated growth in 2026 [1][2][6] - High-value consumables and equipment performed relatively well in the first half of the year, with upstream medical device companies like Meihao Medical, Yingke Medical, and Haitai Xinguang showing high growth trends in Q3 [1][3][4] Key Trends and Insights - The strategy of expanding overseas is crucial for Chinese medical device companies to unlock a second growth curve, driven by domestic policy pressures and increased competition from local manufacturers [1][5] - The medical device sector is expected to see a significant improvement in Q3, with companies like Union Medical and Mindray anticipated to show performance turning points [4][8] - The high consumables segment is expected to see further improvement in Q3, benefiting from reduced impact from centralized procurement and the launch of new products, with companies like Huatai and Maipu Chunli Medical projected to achieve high growth [9] Investment Opportunities - Companies with high growth potential or rapid profit growth, such as Meihao Medical and those in the brain-computer interface and humanoid robot supply chains, are recommended for long-term holding [6][7] - Low-valuation companies expected to accelerate growth in 2026 include Meihao Medical, MicroPort Medical, and Yiyuan Technology, among others [12] - The IVD sector is facing challenges but is expected to see improvements in domestic growth rates, while overseas markets maintain high growth [10] Performance of Specific Companies - The Hong Kong medical device sector has shown significant innovation, with companies like Silan Tongqiang and MicroPort Medical demonstrating strong recovery in profitability [14] - The consumption medical services sector, led by Aier Eye Hospital, is outperforming serious medical services, with a notable increase in average transaction prices for procedures [16][17] Valuation and Market Position - The overall valuation of the medical services sector is at historically low levels, with the current PE ratio around the 20% percentile of the past five years [18] - Comprehensive hospitals are facing revenue declines due to healthcare payment reforms, with many experiencing over a 10% drop in income in the first half of 2025 [19][20] Recommendations for Future Monitoring - Long-term investment opportunities exist in both the Hong Kong and A-share medical device sectors, particularly in companies with strong innovation capabilities and international expansion potential [15] - Companies like Aier Eye Hospital and Hai Jiaya Medical are recommended for their leadership in their respective segments, while Yiyuan Medical is noted for its rapid overseas growth and strong cash flow [21][22]

Core Viewpoint - The stock price of United Imaging Healthcare has shown fluctuations, with a year-to-date increase of 16.19% and a recent decline of 3.19% over the past five trading days [2]. Financial Performance - For the first half of 2025, United Imaging Healthcare reported a revenue of 6.016 billion yuan, representing a year-on-year growth of 12.79%, and a net profit attributable to shareholders of 999.8 million yuan, which is a 5.03% increase compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 534 million yuan [3]. Stock Market Activity - As of September 24, the stock price reached 146.77 yuan per share, with a trading volume of 588 million yuan and a turnover rate of 0.49%, resulting in a total market capitalization of 120.962 billion yuan [1]. - The net outflow of main funds was 48.8142 million yuan, with large orders accounting for 23.48% of purchases and 31.48% of sales [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 23.01% to 16,500, with an average of 35,953 circulating shares per person, which is an increase of 29.89% [2]. - Major shareholders include the Huaxia SSE STAR 50 ETF, which increased its holdings by 3.2169 million shares, and the Hong Kong Central Clearing Limited, which increased its holdings by 781,970 shares [3].

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 50 Index (000688) has seen a strong increase of 1.74%, with notable gains from component stocks such as Shengmei Shanghai (688082) up 9.99%, Huahai Qingshi (688120) up 7.10%, and Hehui Optoelectronics (688538) up 7.04% [1] - The Sci-Tech 50 ETF Index (588040) also rose by 1.74%, with the latest price reported at 1.46 yuan [1] - Semiconductor equipment is leading the market, with Shengmei Shanghai reaching a new high following the announcement of its first KrF process front-end coating and developing equipment, Ultra Lith KrF, which was delivered to a major logic wafer factory in China on September 8, 2025 [1] Group 2 - The Sci-Tech 50 ETF Index closely tracks the performance of the Sci-Tech Innovation Board 50 Index, which consists of 50 securities with large market capitalization and good liquidity, reflecting the overall performance of representative sci-tech enterprises [2] - As of August 29, 2025, the top ten weighted stocks in the Sci-Tech Innovation Board 50 Index include Cambricon (688256), SMIC (688981), Haiguang Information (688041), and others, collectively accounting for 60.25% of the index [2] - The Sci-Tech 50 ETF Index is complemented by other products such as the Sci-Tech 50 Enhanced ETF (588460) and various connection funds [2]

Investment Rating - The report recommends focusing on leading companies in various segments of the high-value consumables and medical device sectors, indicating a positive outlook for recovery and growth in these areas [4][30]. Core Insights - High-value consumables have begun to recover from the impacts of centralized procurement, with leading companies regaining profitability levels seen before the procurement initiatives [4][32]. - The medical device and IVD sectors are expected to show signs of recovery, with significant improvements anticipated in financial performance by Q3 2025 for device companies and by Q4 2025 for IVD companies [4][30]. - The report highlights specific high-growth segments, including vascular intervention, orthopedics, and IVD, suggesting that these areas will continue to attract investment due to their growth potential and market dynamics [4][30]. Summary by Sections Medical Devices - The medical device sector is projected to experience a revenue decline in 2024, with a further drop of -5.18% expected in the first half of 2025, but recovery is anticipated thereafter [9][12]. - Despite revenue challenges, the overall gross margin and net profit margin have remained stable, with R&D expenses increasing from approximately 7% pre-pandemic to around 10% currently [10][12]. - Companies in the imaging equipment segment are expected to see improved performance in Q3 2025 as inventory issues are resolved and new procurement projects are executed [13][18]. High-Value Consumables - The high-value consumables sector has shown revenue growth in the first half of 2025, indicating a recovery from previous declines, with profit margins returning to levels seen in 2021 [32][33]. - Specific segments such as vascular intervention and orthopedics are highlighted for their resilience and growth potential, with companies like Huatai Medical and Weigao Orthopedics showing significant revenue increases [38][43]. IVD and Other Segments - The IVD sector is expected to see improvements by Q4 2025, with overall industry recovery projected for the first half of 2026 [4][30]. - The report emphasizes the importance of innovation and market expansion for companies in the rehabilitation and home medical device sectors, with firms like Sanofi and Kefu Medical showing strong growth despite market challenges [24][26].